Skip to main content

sec filings

Insider trades

Open-market buys and sales that company insiders report to the SEC on .

Side
Planned sales
Role
STLN

Updated 10/6/2026, 8:56 AM ET.

STLN

Starling Oncology, Inc.

Sale$1,946,310

Hively Brad

Director

298,853 shat $6.51Filed Aug 24, 5:11 PM ET
Filing
STLN

Starling Oncology, Inc.

Buy$78,480

Chernett Jorey

10% owner

12,000 shat $6.54Filed Aug 17, 10:13 AM ETFiling

Read from public SEC filings. Not financial advice.